Introduction {#s1}
============

The process of RNA polymerase II (RNAPII) recruitment to protein coding genes is part of the assembly of the Pre-Initiation Complex (PIC) that is typically nucleated by TFIID-mediated recognition of core promoter sequences. The TFIID complex is composed of TATA-box binding protein (TBP) and TBP-associated factors (TAFs) ([@bib36]; [@bib42]). Moreover, several TBP-related factors (TRFs) have been identified ([@bib1]), expanding the repertoire and versatility of the basal transcription machinery ([@bib34]; [@bib16]; [@bib33]). While a number of events contribute to promote PIC assembly, including sequence-specific transcriptional activators, chromatin remodeling complexes and histone modifications, recent work has proposed that changes in the identity of PIC components is a key determinant of cell type-specific gene expression ([@bib17]; [@bib6]).

In particular, it was recently suggested that during skeletal muscle differentiation, canonical TFIID is replaced by a complex consisting of TBP2 (also termed TRF3 = TBP-related factor 3; gene name Tbpl2 = TATA box binding protein like 2) and TAF3, which is required for activation of muscle genes ([@bib6]; [@bib7]). Further work has revealed that the alternative core factor TAF3, which is known to recognize histone H3K4me3 - a histone modification associated with active promoters ([@bib46]; [@bib45]; [@bib25]; [@bib40]) - mediates interactions between MyoD, permissive chromatin and PICs at promoters of muscle-specific genes ([@bib7]; [@bib48]). This finding suggested that the widely established paradigm of a universal and prevalent use of TFIID as a promoter-recognizing complex in a variety of somatic cells might undergo drastic change during development. Nevertheless this hypothesis has been challenged by the observation that TBP2 null (TBP2_KO = TBP2 knock out) mice do not display any skeletal muscle phenotype ([@bib15]), indicating that TBP2 is dispensable for developmental myogenesis (see [http://www.europhenome.org/databrowser/viewer.jsp?set=true&m=true&x=Both Split&ln=Tbp2&project=All&zygosity=All&m=true&l=10386](http://www.europhenome.org/databrowser/viewer.jsp?set=true&m=true&x=Both%20Split&ln=Tbp2&project=All&zygosity=All&m=true&l=10386)). However, Gazdag et al. did not explore the integrity of the regeneration potential of skeletal muscles in TBP2 null mice during adult life, and thus have not ruled out the possibility that TBP2 can specifically promote the expression of muscle genes in muscle stem (satellite) cells (MuSCs) - the direct effectors of post-natal and adult skeletal myogenesis ([@bib5]).

MuSCs are usually found beneath the basal lamina of unperturbed muscles in a dormant state (quiescence) ([@bib31]), but are rapidly activated upon damage to give rise to new, differentiated myofibers through extensive epigenetic reprogramming ([@bib12]; [@bib38]; [@bib32]). Two key molecular events that invariably coincide with MuSC activation and commitment toward myogenic differentiation are (i) the expression of skeletal muscle transcription master regulator MyoD ([@bib49]; [@bib41]) and (ii) the activation of the p38 signaling ([@bib22]). These pathways cooperate to promote SWI/SNF-mediated chromatin remodeling and to increase levels of the active chromatin mark H3K4me3 ([@bib2]) at promoters of muscle genes ([@bib39]; [@bib35]; [@bib13]). Indeed, studies from the Rando group have revealed that in activated MuSCs the large majority of muscle gene promoters show enrichment in H3K4me3 ([@bib28]). Collectively, the data described above suggest that the H3K4me3 chromatin mark can mediate TAF3 recruitment to MyoD-target genes in activated MuSCs. Since TAF3 has been proposed as a mediator of TBP2 recruitment to muscle gene promoters ([@bib7]; [@bib48]), these data provide the rationale for investigating whether TBP2 deficiency can impair post-natal and adult skeletal myogenesis.

Results {#s2}
=======

TBP2 ablation does not affect MuSC differentiation and muscle regeneration after muscle injury {#s2-1}
----------------------------------------------------------------------------------------------

To investigate the role of TBP2 in postnatal and adult skeletal myogenesis in vivo we assessed the muscle regeneration potential of TBP2 null mice ([@bib15]) in response to injury. Notexin-mediated muscle injury triggers extensive muscle damage and stimulates adult muscle regeneration and post-natal myogenesis in vivo, during which damaged muscle is replaced by newly formed myofibers arising from activated MuSCs. Histological assessment of regenerating muscles showed a complete recovery of the muscle architecture, with abundant presence of centrally nucleated fibers in both wild type (WT) and TBP2 null muscles at 12 days post injury - a time point when muscle regeneration is near completion ([Figure 1A](#fig1){ref-type="fig"}). Both WT and TBP2 null mice contain similar numbers of Pax7 positive MuSCs in a sub-laminar position within unperturbed muscles ([Figure 1B](#fig1){ref-type="fig"} upper panel, 1C). This result indicates that there are no defects in MuSC ontogenesis in the absence of *Tbpl2* expression. Importantly, we detected comparable numbers of MuSCs in muscles of WT and TBP2 null mice 12 days after injury ([Figure 1B](#fig1){ref-type="fig"} lower panel, [1C](#fig1){ref-type="fig"}), indicating an intact capacity of adult MuSCs to proliferate, self-renew and differentiate during ongoing muscle regeneration in the absence of TBP2. Finally, we used Fluorescence Assisted Cell Sorting (FACS) to isolate MuSCs from skeletal muscles of WT and TBP2 null mice before and 12 days after notexin-mediated injury, and analyzed their intrinsic myogenic potential ex vivo Cultures of MuSCs from all conditions yielded a comparable number of Myosin Heavy Chain (MHC)-positive multinucleated myotubes ([Figure 1D,E](#fig1){ref-type="fig"}), demonstrating that MuSCs from TBP2 null muscles have the identical myogenic potential of MuSCs from WT mice as they can readily differentiate into myotubes with equal capacity upon exposure to differentiation conditions in vitro.10.7554/eLife.12534.003Figure 1.Regenerative potential and differentiation of MuSCs are intact in the absence of TBP2.(**A**) Cross-sections of unperturbed (left panel) and notexin injured (right panel) muscles were histologicaly assessed by Hematoxilin/Eosin (H&E) staining to evaluate the muscle architecture 12 days post notexin-mediated injury of the muscle. Size bar 100 µm. Representative image of muscles analyzed from two WT and two TBP2_KO mice are presented. (**B**) Representative images of cross-sections of unperturbed and of notexin injured muscles were immunolabeled with anti-laminin B2 (green) and anti-Pax7 (red) antibodies. Nuclei were counterstained with DAPI (blue). Pax7-positive MuSCs (Muscle Stem cells - Satellite cells) in sub-laminar position are indicated by an arrow. Size bar 200 µm. (**C**) Quantification of Pax7-positive MuSCs residing in sub-laminar position in B. Muscles from two mice have been analyzed and for each point, three different areas of the muscle were taken into account. Error bars represent a standard deviation among biological replicates. Student's *t* test was used for statistical analyses in C and E, n.s. - not significant. (**D**) MuSCs were isolated by FACS-assisted analysis as CD45-/CD31-/Ter119-/Sca1-/CD34+/alpha7intergrin+ from unperturbed and from notexin injured (12 days post injury) muscles. Isolated MuSCs were in vitro differentiated into myotubes, and immuno-labeled with anti-Myosin Heavy Chain (MHC) antibody (green) to monitor myotubes formation. The nuclei were counterstained with Hoechst 33,258 (blue). Images were taken by Olympus IX71 microscope with 10x objective. Representative images of differentiated MuSCs are presented. Size bar 50 µm. (**E**) Quantification of nuclei residing within MHC-positive differentiated MuSCs myotubes in D. Differentiation index is presented as% on nuclei within MHC-positive myotubes. Error bars represent a standard deviation between two independent MuSC isolations, each cultured and quantified in triplicate. Student's *t* test was used for statistical analyses in C and E, n.s. - not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.12534.003](10.7554/eLife.12534.003)

Our in vivo data on adult muscle regeneration, as well as the intact differentiation potential of *Tbpl2*-lacking MuSCs ex vivo demonstrate that TBP2 is dispensable for adult skeletal muscle differentiation.

TBP2 is not expressed in myotubes {#s2-2}
---------------------------------

Our data demonstrating the lack of requirement of TBP2 for adult skeletal muscle regeneration prompted us to compare the RNA expression profile of *Tbp* and *Tbpl2* genes in MuSCs isolated from skeletal muscles of wild type mouse by FACS, and in the C2C12 myogenic cell line ([@bib3]). *Tbp* expression was detected in both MuSC-derived myotubes and in C2C12 myotubes ([Figure 2A](#fig2){ref-type="fig"}). On the contrary, we could not detect *Tbpl2* expression in myotubes derived from MuSCs or C2C12s ([Figure 2A](#fig2){ref-type="fig"}). *Ckm* RNA expression in MuSCs and in C2C12 confirms that cells were differentiated into mytubes. As a control for *Tbpl2* RNA detection, we analyzed total RNA extracted from murine ovary tissue ([Figure 2A](#fig2){ref-type="fig"}), as previous work demonstrated the ovary-specific expression of TBP2 in mice ([@bib15]). Independent analysis of publicly available RNA-seq data from C2C12 myoblasts and myotubes ([@bib43]) and of our RNA-seq data from MyoD-converted human fibroblasts, further confirmed the absence of *Tbpl2* expression in skeletal myoblasts and myotubes ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).10.7554/eLife.12534.004Figure 2.TBP2 is not expressed in myotubes.(**A**) RT-PCR analysis of RNA isolated from MuSC-derived myotubes, and from C2C12-derived myotubes. RNA isolated from murine ovaries was used as a control for *Tbpl2* expression (gene coding for TBP2 protein). Relative expression of indicated genes is presented as a fraction of *Gapdh* expression. Biological triplicates, error bars represent standard deviation. (**B**) Immunoblot analysis of the whole cell lysate of C2C12 myotubes exogenously expressing murine *Tbpl2* gene (mTBP2) or with a control plasmid. (**C**) RNA expression of indicated genes after exogenous expression of TBP2 in differentiated C2C12 myotubes. Biological triplicates, error bars represent standard deviation. Student's *t* test was used for statistical analyses (\*\*\*p \< 0.001, n.s. - not significant). Myotubes in all experiments shown in this figure were collected by careful trypsinization to avoid contamination with undifferentiated reserve cells ([@bib23]).**DOI:** [http://dx.doi.org/10.7554/eLife.12534.004](10.7554/eLife.12534.004)10.7554/eLife.12534.005Figure 2---figure supplement 1.RNA-seq data comparing Tbp and Tbpl2 gene expression in murine C2C12 and in human fibroblasts IMR90 converted by ectopic expression of MyoD.RNA-seq data in C2C12 proliferating moblasts (Myoblasts) and differentiated C2C12 (Myotubes) were generated in B. Wold\'s laboratory (GSE20846) ([@bib43]). RNA-seq data in IMR90 fibroblasts expressing MyoD were generated in our lab (doi:10.5061/dryad.7qk36). GM_IMR90_MyoD sample represents proliferating IMR90 expressing MyoD (Myoblasts) and DM_IMR90_MyoD sample represents IMR90 expressing MyoD and differentiated into myotubes (Myotubes). *Tbp* (gene coding for TBP) and *Tbpl2* (gene coding for TBP2) data are presented, *Ckm* is a marker of terminally differentiated myotubes. RNA-seq data were uploaded to UCSC genome browser for visual representation.**DOI:** [http://dx.doi.org/10.7554/eLife.12534.005](10.7554/eLife.12534.005)

As a further control of accuracy for detection of *Tbpl2* in muscle cells, we transfected C2C12 myoblasts with a murine *Tbpl2*-expressing plasmid and monitored the *Tbpl2* and *Tbp* expression in differentiated C2C12 myotubes by immunoblot analysis of total cell lysates of C2C12 myotubes and by RT-PCR analysis of RNA isolated from C2C12 myotubes ([Figure 2B,C](#fig2){ref-type="fig"}). We could detect the TBP2 protein ([Figure 2B](#fig2){ref-type="fig"}) and *Tbpl2* transcript ([Figure 2C](#fig2){ref-type="fig"}) in C2C12 myotubes only upon ectopic expression of *Tbpl2*. Importantly, the ectopic *Tbpl2* expression in C2C12s did not affect the formation of myotubes and the expression levels of muscle differentiation genes, such as *Myog* and *Ckm* ([Figure 2C](#fig2){ref-type="fig"}). The data we present here demonstrate that *Tbpl2* is not expressed during differentiation of skeletal myoblasts into myotubes.

TBP is required for skeletal muscle differentiation {#s2-3}
---------------------------------------------------

Since TBP levels were reported to be significantly decreased during differentiation of skeletal myoblasts into myotubes ([@bib6]; [@bib50]; [@bib27]), while TBP2 is absent in differentiating myotubes (data reported here), we tested whether lower amounts of TBP would be functional during muscle differentiation. We have effectively downregulated TBP protein levels in C2C12 myoblasts using an siRNA-mediated approach ([Figure 3A,C](#fig3){ref-type="fig"}), and exposed them to differentiation conditions. While C2C12s transfected with control siRNA readily differentiated into large multinucleated myotubes within 48 hr ([Figure 3A](#fig3){ref-type="fig"}, siCTR), C2C12 myoblasts with undetectable TBP protein levels failed to differentiate ([Figure 3A](#fig3){ref-type="fig"}, siTBP). We have quantified the differentiation index, the percentage of nuclei within myotubes of differentiated C2C12, to illustrate better the impaired differentiation potential of C2C12 in the absence of TBP ([Figure 3B](#fig3){ref-type="fig"}). mRNA analysis of skeletal muscle specific genes *Myog, Ckm* and *Acta1* demonstrates an impaired activation of the skeletal muscle program in the absence of TBP ([Figure 3D](#fig3){ref-type="fig"}). Thus, although TBP levels are reduced in myotubes compared to myoblasts under physiological conditions ([@bib6]), near complete TBP elimination impairs muscle differentiation. We conclude that TBP is required for skeletal muscle differentiation.10.7554/eLife.12534.006Figure 3.TBP is required for myoblast differentiation into myotubes.(**A**) Representative images of C2C12 myoblasts differentiation into myotubes upon TBP downregulation. TBP was downregulated using *Tbp*-targetting siRNA in C2C12 myoblasts. C2C12 myoblasts were differentiated into myotubes for two days, and immunolabeled with anti-Myosin Heavy Chain (MHC) antibody (red) to monitor myotybes formation. The nuclei were counterstained with Hoechst 33,258 (blue). Images were taken by Olympus IX71 microscope with 20x objective. Size bar 20 µm. (**B**) Quantification of nuclei residing within differentiated MHC-positive myotubes in A, represented as differentiation index. Error bars represent a standard deviation among three biological replicates. Student's *t* test was used for statistical analyses (\*\*\*p\<0.001). (**C**) Immunoblot analysis of the whole cell lysate of C2C12 to assess the TBP protein levels after siRNA-mediated silencing of TBP. (**D**) mRNA isolated from C2C12s grown in differentiation medium after siRNA-mediated downregulation of TBP was analyzed by RT-PCR for expression of skeletal muscle specific genes *Myog, Ckm* and *Acta1*. Relative expression of indicated genes is presented as a fraction of *Gapdh* expression. Error bars represent a standard deviation among three biological replicates. Student's *t* test was used for statistical analyses (\*\*\*p \< 0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.12534.006](10.7554/eLife.12534.006)

The TFIID complex is expressed in myoblasts and myotubes {#s2-4}
--------------------------------------------------------

The requirement of TBP for skeletal muscle differentiation and the absence of TBP2 in skeletal myotubes suggest that the TFIID complex may be present in myogenic cells and may drive muscle gene transcription during myoblast differentiation into myotubes. To test this hypothesis we have set out to detect expression of TAF subunits of the TFIID complex in both cultured C2C12 and MuSC myoblasts and myotubes at the RNA and protein levels. We observe a downregulation of mRNA expression of the TFIID subunits TBP and TAFs in myotubes derived from both C2C12s ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) and from MuSCs ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}), compared to undifferentiated cells (myoblasts). Next, we further analyzed the protein levels of TFIID subunits in myoblasts and in myotubes by immunoblot analysis ([Figure 4A](#fig4){ref-type="fig"}). Indeed, TFIID subunits were detected in C2C12 nuclear extracts prepared from both proliferating myoblasts and differentiated myotubes, with a concomitant downregulation of most TFIID subunits also at the protein level ([Figure 4A](#fig4){ref-type="fig"}), as previously observed ([@bib6]; [@bib50]). To demonstrate the purity of the myoblasts and myotubes isolated in our experimental conditions, we monitored the protein expression of the cell cycle protein Cyclin D1, which is typically expressed in myoblasts and downregulated during muscle differentiation ([Figure 4A](#fig4){ref-type="fig"}). We also analyzed markers of myogenic differentiation, such as Myogenin, Myosin Heavy Chain (MHC) and Actinin 3, ([Figure 4A](#fig4){ref-type="fig"}). Expression of these proteins is specific for either myoblasts (Cyclin D1) or myotubes (Myogenin, MHC, Actinin 3), and demonstrates the high purity of the cell populations used in our study, confirming that detection of TFIID subunits in myotubes is not due to contamination with undifferentiated myoblasts.10.7554/eLife.12534.007Figure 4.TFIID complex is present in proliferating myoblasts and differentiated myotubes.(**A**) Immunoblot analysis from nuclear extracts was used to determine protein levels of TFIID subunits TBP, TAF1, TAF2, TAF4, TAF6, TAF10, TAF12 expressed in proliferating myoblasts (MB) and differentiated myotubes (MT). Myoblast-specific expression of Cyclin D1 and myotube-specific expression of muscle markers Myogenin, MHC and Actinin 3 are used as markers of C2C12 differentiation. Ponceau staining of proteins on the immunoblot membrane was used as a loading control. Representative experiment is show. (**B**) Immunoprecipitation of endogenous TBP from C2C12 nuclear extract results in co-immunoprecipitation of TAF4 and TAF6 subunits of TFIID in both myoblasts (MB) and myotubes (MT). (**C**) 10--55% glycerol gradient size fractionation assay monitors co-fractionation of TFIID subunits TBP, TAF4 and TAF6 in high molecular weight fractions with a signal peaking in fractions corresponding to 0.6--1 MDa in both myoblasts (lower panel) and myotubes (upper panel).**DOI:** [http://dx.doi.org/10.7554/eLife.12534.007](10.7554/eLife.12534.007)10.7554/eLife.12534.008Figure 4---figure supplement 1.Evaluation of TFIID subunit expression on RNA level during C2C12 and Satellite cells (MuSCs) differentiation.Reverse Transcription - PCR (RT-PCR) analysis of RNA isolated from proliferating and differentiated (**A**) C2C12 and (**B**) Satellite cells (MuSCs). Signal is represented as a fraction of *Gapdh* expression levels. Myotubes were collected by careful trypsinization ([@bib23]). Error bars represent a standard deviation among three biological replicates. Student's *t* test was used for statistical analyses (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.12534.008](10.7554/eLife.12534.008)

Next we analyzed the physical association between TBP and TAFs, as well as the integrity of the TFIID complex in C2C12 myoblasts and myotubes. Immunoprecipitation of endogenous TBP from nuclear extract prepared from C2C12 myoblasts and myotubes demonstrated an association of mTBP with mTAF4 and mTAF6 core subunits of TFIID in both proliferating and differentiated C2C12s ([Figure 4B](#fig4){ref-type="fig"}), further demonstrating the presence of the TFIID complex in myoblasts as well as in myotubes. Size fractionation of nuclear extracts from C2C12 myoblasts or myotubes by glycerol gradient centrifugation revealed the presence of TFIID subunits TBP, TAF4 and TAF6 in a high molecular weight fraction of about 0.6--1 MDa, thus detecting the TFIID complex in both myoblasts and myotubes ([Figure 4C](#fig4){ref-type="fig"}), at the same size previously described in human HeLa cells ([@bib9]).

Altogether, our results are contrary to previously reported data ([@bib6]) and demonstrate that the TFIID complex is not replaced by TBP2 upon myogenic differentiation.

TBP is recruited to MyoD target genes during differentiation {#s2-5}
------------------------------------------------------------

The requirement of TBP for skeletal muscle differentiation prompted us to further analyze the dynamics of the PIC assembly on muscle promoters during C2C12 myoblast-to-myotube differentiation. Upon exposure of myoblasts to differentiation cues, we detected recruitment of TBP and RNA polymerase II phosphorylated on Serine 5 of its carboxy-terminal domain CTD (RNAPII-S5P), the transcription initiating form of RNAPII ([@bib19]; [@bib24]), on muscle gene promoters regulated by MyoD ([Figure 5](#fig5){ref-type="fig"}). TBP and RNAPII-S5P were not detected on these promoters in proliferating myoblasts, when the muscle genes are inactive ([Figure 5](#fig5){ref-type="fig"}), further supporting the evidence that TBP drives MyoD-mediated activation of muscle-specific gene transcription during muscle differentiation. TBP and RNAPII-S5P were present on the constitutively active *Gapdh* promoter in myoblasts and myotubes, but not on transcriptionally silent loci such as the *Sox2* promoter and the *Igh* enhancer ([Figure 5](#fig5){ref-type="fig"}). Thus, our data demonstrate the direct involvement of TBP in nucleating PIC assembly at MyoD-regulated skeletal muscle promoters during muscle differentiation.10.7554/eLife.12534.009Figure 5.TBP is recruited to muscle genes upon muscle differentiation.Chromatin Immunoprecipitation (ChIP) assay in proliferating C2C12 myoblasts and differentiated C2C12 myotubes monitors recruitment of TBP and RNAPII-S5P components of PIC at promoters of skeletal muscle genes *Myog, Acta1, Ttn, Pdlim3, Mylpf* and *Mybph*. Transcriptionally active *Gapdh* promoter and inactive *Sox2* promoter and *Igh* enhancer were used as controls. Signal of relative recruitment is represented as a percentage of input DNA. Representative experiment of two independent biological replicate experiments is shown.**DOI:** [http://dx.doi.org/10.7554/eLife.12534.009](10.7554/eLife.12534.009)

Discussion {#s3}
==========

In this work, we demonstrate that TBP, but not TBP2, is the essential component of the PIC that promotes muscle gene expression in differentiated skeletal muscles. We found that TBP2 is not expressed in myotubes derived from either C2C12 myoblasts, nor from primary mouse MuSCs. Consistently, TBP2-deficient mice displayed an intact regeneration potential, and MuSCs isolated from TBP2-deficient muscles differentiated into myotubes with the same efficiency as wild type MuSCs. This evidence firmly supports the conclusion that TBP2 does not replace TBP during muscle differentiation, as previously proposed by Deato et al. ([@bib6]).

We have observed downregulation of TFIID subunits at both the RNA and protein levels in differentiated myotubes, compared to proliferating myoblasts, as has previously been reported ([@bib6]; [@bib50]). Recently, a mechanism for ubiquitination-mediated downregulation of TBP protein in skeletal myotubes was reported ([@bib27]). Therefore, the plausible scenario in skeletal muscle specific transcription is that limited TFIID helps to restrict the assembly of the transcription competent PIC at a selected subset of muscle specific genes.

Our findings that TBP/TFIID is functional in muscle progenitors and their differentiated progeny are in agreement with earlier studies showing that TBP was able to bind the MyoD promoter in a TATA-dependent manner ([@bib26]). It has been also shown that MyoD efficiently stimulated TFIID-dependent basal transcription ([@bib18]; [@bib11]). Moreover, an endogenous interaction between MyoD and TBP in both myoblasts and myotubes was demonstrated, and in myotubes, MyoD and components of PIC TBP and TFIIB were found to be recruited to the proximal promoter of the *alpha-sarcoglycan* muscle gene promoter ([@bib8]). The relevance of TBP-mediated activation of MyoD target genes has been recently emphasized by the finding that large polyglutamine (PolyQ) repeats in TBP causes muscle degeneration, by reducing the expression of muscle-specific genes, due to a decreased association of TBP with MyoD ([@bib20]). This finding reiterates the importance of clarifying the identity of the proteins that compose the core promoter basal machinery required for muscle gene transcription in differentiating muscles, further extending the related implications to the pathogenesis of human muscular disorders.10.7554/eLife.12534.010Table 1.Squences of the primers used in this study.**DOI:** [http://dx.doi.org/10.7554/eLife.12534.010](10.7554/eLife.12534.010)Mouse primers for RT-PCRGapdh-forGCTCACTGGCATGGCCTTCCGGapdh-revGTAGGCCATGAGGTCCACCACMyog-forGAGACATCCCCCTATTTCTACCAMyog-revGCTCAGTCCGCTCATAGCCActa1-forAOCGTTTCCGTTGCCCOOAGActa1-revGGAGAGAGAGCGCGAACGCATtn-forGACACCACAAGGTGCAAAGTCTtn-revCCCACTOTTCTTGACCGTATCTPdlim3-forTGGGGGCATAGACTTCAATCAPdlim3-revCTCCGTACCAAAGCCATCAATAGMylpf-forTTCAAGGAGGCGTTCACTQTAMylpf-revTAOCGTCOAGTTCCTCATTCTMybph-forCAGCCACTAAGCCTGAACCTCMybph-revTCCAACACATAGCCTTGAAGCCyclin D1-forACTTCCTCTCCAAAATGCCAGCyclin D1-revGTOGGTTGOAAATGAACTTCACCkm-forAQTCCTACACQQTCTTCAAGOCkm-revAGGAAGTGGTCATCAATQAGCTbpl2-forATACCTGGACCTCTTCCTGOATTbpl2-revCCACCAAGATGTGGATGAAACTbp-forCCAAGCGATTTGCTGCAGTCATCATbp-revACTTAGCTGGGAAGGCCAACTTCTTaf1-forACAGGAACAGATGCAGACCTTCGTTaf1-revAATCTCCTCCTCAGGCACACCAAATaf2-forGGCCTTGGAAAAATTCCCCACTaf2-revGAAGCACGCTGACATCCTGATaf3-forGACATTGATGCTGCGAAAGTGCGATaf3-revTCCCGCTTGCT7CTTTCTCGATCTTaf4-forAGTTCACACGGCAAAGAATCACGCTaf4-revAACGCCGGCTCATCCTGTTACTTATaf5-forTTTC6GACGAGTAAATTCGTTCTTaf5-revCTCCTGCACGATGTTCCAGATTaf6-forAAACTCAGCAATACTGTGTTGCCTaf6-revTTCTGTCGTTTCCCCATGTGCTaf8-forCCGGGAAGTAAGCAATCCACTTaf8-revGCTTTCTCGGCACTCTCAAATCTar9-forTGCCGAAAGATGCACAGATGATaf9-revTGTTGTCACATATCOGAAGGCTaf10-forGAGGGOGCAATQTCTAACGGTaf10-revTGTGTAATCCTCCAACTGCATCTaf12-forGGACAGQTQQTCGTCTCAGTat12-revTCATCAOCOATCTOTAGCAGC**Mouse primers for ChIP**Myoq TSS-forGCTCAGGTTTCTGTGGCGTTMyog TSS-revCCAAC TGCTGGGTGCC ATActa1 T5S-forGTGCCCGACACCCAAATAActa1 TSS-revAGGGTAGGAAGTGAGGCTTTtn TSS-forCCTTCCTAACAGAGCCAATCACTtn TSS-revTGTTTCCTATGCAATCCCTACACPdlim3 TSS-forCACTCGCAGCAGGQATAAATPdlim3 TSS-revGAACCGGACAACCTACTTAGCMylpf TSS-forCTCCAAGCAGATTCTCTTGCTTTMylpf TSS-revGGTAGOGC TAT CC T OAOCTAATMybph TSS-forGCCTGCCTTTATAAGCATQAACMybph TSS-revGTOTCAAGCTGOAGTOTTTAAGGapdh TSS-forAGQGCTGCAGTCCGTATTTAGapdh TSS-revAGOAGGGGAAATGAGAOAGGSox2 TSS-forGATTGGCCGCCGQAAACSox2 TSS-revCTCTTCTCTOCCTTOACAACTCIgh enhancer-forAACCACAGCTACAAGTTTACCIgh enhancer-revAACCAGAAÇACCTGCAGCAGC

Materials and methods {#s4}
=====================

Animals and muscle injury {#s4-1}
-------------------------

All protocols were approved by the Sanford-Burnham Medical Research Institute Animal Care and Use Committee. C57/BL6 TBP2_KO (TBP2 null; TBP2^-/-^) mice were described previously ([@bib15]). The mouse colony was maintained by breeding heterozygous females TBP2^+/-^ with heterozygous males TBP2^+/-^. Acute injury and muscle regeneration were induced in TBP2 null mice or in the wild type (WT) littermates by intramuscular injection of 10 µl of 10 μg/ml notexin (NTX, Latoxan, Valence, France) into the tibialis anterior (TA), gastrocnemius and quadriceps muscles. Mice were sacrificed 12 days post injury. Muscles were snap frozen in liquid nitrogen-cooled isopentane and cut transversally using a Leica CM 3050 S cryostat. Muscle regeneration was evaluated histologically on 10 µm cryo-sections of muscles.

Histology {#s4-2}
---------

For Hematoxylin and Eosin staining (H&E, HT110-3, Sigma, St. Luis, MO), 10 µm muscle cryo-sections were stained in hematoxylin for 3 min and eosin Y for 2 min, according to the instructions. Stained cryosections were dried in ethanol and fixed in xylene, and slides were mounted with EUKITT mounting (O. Kindler GmbH & CO, Freiburg, Germany). Images were acquired using an inverted epifluorescent microscope (Nikon TE300, Tallahasee, FL), 10x objective lens. All images were processed using ImageJ. For Pax7 immunofluorescence experiments, 10 µm muscle cryosections were fixed in 1.5% paraformaldehyde for 15 min and permeabilized with 0.3% Triton-X. To avoid non-specific binding, muscle sections were blocked with 20% goat serum (Gibco by Thermo Fisher Scientific, Waltham) in PBS. Immunolabeling with a rat anti-Laminin B2 (05--206, Millipore, Billerica, MA, USA) antibody was performed overnight at 4°C, followed by labeling with secondary anti-rat antibody coupled with Alexa Fluor 488 (Molecular Probes, Thermo Fisher Scientific, Waltham, MA, USA). Next, the antigen retrieval was performed using the Antigen Unmasking Reagent (Vector Laboratories, Burlingame, CA, USA) at 100°C for 15 min. Specimens were next labeled with mouse anti-Pax7 antibody (PAX7, Developmental Studies Hybridoma Bank, Iowa City, IA, USA) in 20% goat serum and 0.3% Triton-X in PBS overnight at 4°C, followed by labeling with a secondary anti-mouse antibody coupled with Alexa Fluor 546 (Molecular Probes). Nuclei were visualized by counterstaining with DAPI (Molecular Probes, Thermo Fisher Scientific, Waltham, MA, USA). Images were captured using a Zeiss LSM 710 Multiphoton microscope equipped with Zen Software (Zeiss, Pleasanton, CA, USA) and subsequently edited in ImageJ.

FACS isolation of Satellite cells (MuSCs) {#s4-3}
-----------------------------------------

Satellite cells were isolated from hind limb muscles of WT and TBP null mice, either unperturbed or 12 days post acute injury by fluorescence-activated cell sorting (FACS), as previously described ([@bib37]). Hind limb muscles were mechanically minced and enzymatically digested in HBSS with Mg^2+^ and Ca^2+^ (Gibco by Thermo Fisher Scientific, Waltham, MA, USA) containing 0.2% (w/v) BSA and 10 Units/ml Penicillin + 10 µg/ml Streptomycin (Gibco by Thermo Fisher Scientific, Waltham, MA, USA), 2 mg/ml Collagenase A (Roche, Mannheim, Germany), 2.4 U/ml Dispase I (Roche, Mannheim, Germany), 10 µg/ml DNase I (Roche, Mannheim, Germany), 0.4 mM CaCl~2~ and 5 mM MgCl~2~ and 0.2% (w/v) Bovine Serum Albumin (BSA) for 90 min at 37°C. The cell suspension was filtered through a 100 µm nylon cell strainer (BD Falcon, Tamaulipas, Mexico), followed by filtration through 40 µm nylon cell strainer (BD Falcon). Cells were labeled with primary antibodies: CD31-PacificBlue (RM5228, Life Technologies by Thermo Fisher Scientific, Waltham, MA, USA), CD45-eFluor450 (clone 30-F11, eBioscience, San Diego, CA, USA), Ter119-eFluor450 (clone TER-119, eBioscience), Sca-1-FITC (clone E13-161.7, BD Pharmingen, by BD Biosciences, San Josa, CA, USA), CD34-APC (clone RAM34, BD Pharmingen) and α7integrin-PE (clone R2F2, AbLab, Vancouver, Canada) for 30 min at 4°C, in a HBSS buffer with Mg^2+^ and Ca^2+^ containing 0.2% (w/v) BSA and 10 Units/ml Penicillin + 10 µg/ml Streptomycin. Cells were washed and resuspended in HBSS with Mg^2+^ and Ca^2+^ containing 0.2% (w/v) BSA and Penicillin /Streptomycin. Dead cells were stained with Propidium Iodide (PI) (Sigma, St. Luis, MO, USA). Live PI-negative satellite cells were isolated as Ter119-/CD45-/CD31-/CD34+/α7-integrin+/Sca-1- cells. Fluorescence Activated Cell Sorting (FACS) was performed at the Sanford Burnham Prebys Medical Discovery Institute Flow Cytometry Core using a FACSAria instrument, and the data were analyzed by FACSDiva 6.1.3 software.

Culture conditions for Satellite cells (MuSCs) {#s4-4}
----------------------------------------------

FACS isolated satellite cells were plated in laminin-coated tissue culture plates, in culture media containing 50% F10 media (Gibco by Thermo Fisher Scientific, Waltham, MA, USA), 50% DMEM media with low glucose (Gibco by Thermo Fisher Scientific, Waltham, MA, USA), containing 15% Fetal Bovine Serum (HyClone, Logan, UT, USA), 2.5 ng/ml basic fibroblast growth factor (bFGF, PrepoTech Inc. Rocky Hill, NJ, USA), and 10 Units/ml Penicillin + 10 µg/ml Streptomycin. After five days of culture, satellite cells were shifted to differentiation media containing DMEM High glucose (HyClone, Logan, UT, USA), 2% Horse serum (Gibco by Thermo Fisher Scientific, Waltham, MA, USA) and ITS liquid media supplement (Sigma, St. Luis, MO, USA) for an additional 3 days. Culture media was refreshed every two days.

Immunofluorescence in Satellite cells (MuSCs) {#s4-5}
---------------------------------------------

Cultured differentiated Satellite cells were fixed in 4% paraformaldehyde in PBS for 15 min and permeabilized with 0.25% Triton-X in PBS for 10 min at room temperature. To avoid non-specific binding, cells were blocked with 20% goat serum in PBS for 30 min. Immunolabeling with anti-Myosin Heavy Chain (MHC) primary antibody (clone MF20, Developmental Studies Hybridoma Bank) in 5% goat serum overnight at 4°C. Secondary anti-mouse antibody coupled to Alexa Fluor 488 (Molecular Probes) was used to detect MHC signal in myotubes. Nuclei were counterstained with Hoechst 33258 (Life Technologies by Thermo Fisher Scientific, Waltham, MA, USA). Images were taken with Olympus fluorescent microscope with 10x magnification.

C2C12 culture, differentiation and collection {#s4-6}
---------------------------------------------

C2C12 myoblasts were obtained from ATCC (Manassas, VA, USA) and cultured in DMEM High glucose media (growth media = GM) containing 15% Fetal Bovine Serum at low confluency. For differentiation, C2C12 cells were grown to 90% confluence and shifted to differentiation medium (DM) DMEM high glucose containing 2% horse serum and ITS Liquid Media Supplement for two days. Proliferating myoblasts were collected by scraping, while differentiated myotubes were collected by careful trypsinization with 0.05% Trypsin-EDTA (Gibco by Thermo Fisher Scientific, Waltham, MA, USA) to avoid contamination of myotubes by reserve cells ([@bib23]). After collection, C2C12 cells were washed with cold PBS containing 1 mM PMSF (Sigma, St. Luis, MO, USA). Collected C2C12 cells were frozen and stored at -80°C.

Exogenous expression of mTBP2 {#s4-7}
-----------------------------

C2C12 myoblasts were transfected with a pSG5-mTBP2 expressing plasmid ([@bib14]) or a control empty plasmid using Fugene HD transfection reagent (Promega, Madison, WI, USA) according to manufacturer\'s recommendation. Two days post-transfection, when C2C12 myoblasts were 90% confluent, cells were shifted to a differentiation medium (DM) DMEM high glucose containing 2% horse serum and ITS Liquid Media Supplement for two days. Differentiated myotubes were collected for RNA and protein analysis by careful trypsinization ([@bib23]) as described above.

siRNA-mediated downregulation of TBP {#s4-8}
------------------------------------

C2C12 cells were transfected by forward transfection with 80 nM siRNA against *TBP* gene (siTBP, On Target plus Smart Pool L-041188-01, Dharmacon by Thermo Fisher Scientific, Waltham, MA, USA) or non-targeting siRNA (siCTR, D-002050-01-20, Dharmacon) using Lipofectamine RNAiMAX (Life Technologies by Thermo Fisher Scientific, Waltham, MA, USA) according the manufacturer\'s instructions. Two days post transfection, 90% confluent cells were shifted to differentiation media (DM) containing 2% horse serum with ITS supplement. Cells were collected after two days of differentiation in DM for further analysis by immunoblot and for RNA analysis.

RNA analysis {#s4-9}
------------

RNA from C2C12 cells was extracted using RNeasy kit (Qiagen, Hilden, Germany) and the RNA from satellite cells (MuSCs) was extracted using miRNeasy Micro kit (Qiagen) following the manufacturer's protocol. cDNA was synthetized using QuantiTect Reverse Transcription kit (Qiagen) and analyzed by real-time quantitative PCR using SYBR Green PCR Master Mix (Applied Biosystems by Thermo Fisher Scientific, Waltham, MA, USA). Relative expression was calculated using 2^-∆ct^ method ([@bib29]). Primers used to detect gene-specific cDNA are listed in [Table 1](#tbl1){ref-type="table"} .

Immunofluorescence in C2C12 {#s4-10}
---------------------------

C2C12 cells were fixed in 4% paraformaldehyde in PBS (Santa Cruz, Dallas, TX, USA) for 15 min and permeabilized with 0.5% Triton-X in PBS for 15 min at room temperature. To avoid non-specific binding, cells were blocked with 5% BSA in PBS for 30 min. Immunolabeling with anti-Myosin Heavy Chain (MHC) primary antibody (clone MF20, Developmental Studies Hybridoma Bank) in 5% BSA was done overnight at 4°C. Secondary anti-mouse antibody coupled to Alexa Fluor 555 (Molecular Probes) was used to detect MHC signal in myotubes. Nuclei were counterstained with Hoechst 33258 (Life Technologies by Thermo Fisher Scientific, Waltham, MA, USA). Images were taken with Olympus fluorescent microscope with 20x magnification.

RNA-seq analysis of human IMR90 ectopically expressing MyoD {#s4-11}
-----------------------------------------------------------

Human lung fibroblasts IMR90 (ATCC, Manassas, VA, USA) transfected with doxycycline inducible mouse MyoD were cultured in growth media (GM, DMEM high glucose containing 10% FBS). For the GM time point (proliferating converted myoblasts) MyoD expression was induced with 200 ng/ml of doxycycline (Sigma, St. Luis, MO, USA) 24 hr prior to the collection of cells. For the DM time point (differentiated myotubes), MyoD-expressing IMR90 cells were differentiated into myotubes for 72--96 hr in differentiation media (DM, DMEM high glucose containing 2% horse serum and ITS supplement). RNA was extracted using trizol (Ambion by Thermo Fisher Scientific, Waltham, MA, USA) following manufacturer's instructions. PolyA mRNA library preparation was performed as previously described ([@bib21]) and sequenced on the Hi-Seq2000 platform. Reads were mapped to reference human genome (hg19) using TOPHAT v1.4.0 (<http://tophat.cbcb.umd.edu/>).

Preparation of total cell lysate {#s4-12}
--------------------------------

Cells were lysed in RIPA lysis buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA pH 8.0, 0.5% SDS, 1% NP40, 0.5% Sodium Deoxycholate, 1 mM PMSF and protease and phosphatase inhibitor cocktail (Roche, Mannheim, Germany). Cell lysate was syringed through 29G1/2 needle ten times on ice and diluted five fold with TBS (50 mM TRIS-Cl pH 7.5, 150 mM NaCl) containing protease and phosphatase inhibitor cocktail (Roche). Cell lysates were spun at 14,000 g for 10 min at 4°C and supernatant was saved as soluble protein extract. Protein concentration of soluble cell lysates was determined by BCA assay (Pierce by Thermo FIsher Scientific, Waltham, MA, USA).

Nuclear extract (NE) preparation {#s4-13}
--------------------------------

Nuclear extracts from C2C12 myoblasts and C2C12 myotubes carefully trypsinized ([@bib23]) were prepared as described previously ([@bib10]). For NE preparation, C2C12 cells were thawed on ice and rinsed in 10 ml hypotonic buffer (50 mM Tris-Cl pH 8.0, 5 mM EDTA pH 8.0, 20% glycerol). Next nuclei were gently resuspended in Low Salt buffer (10 mM KCl, 20 mM Tris-HCl, pH 7.2, 0.2 mM EDTA, 1.5 mM MgCl~2~, 10 mM β-mercaptoethanol, 20% glycerol). High Salt Buffer (1 M KCl, 20 mM Tris-HCl, pH 7.2, 0.2 mM EDTA, 1.5 mM MgCl~2~, 10 mM β-mercaptoethanol, 20% glycerol) was added gradually in 10 steps while stirring until the final KCl concentration reached 0.4 M. Proteins were further extracted by incubation at 4°C for additional 30 min. Samples were spun at 20,000 g for 20 min at 4°C. Supernatant containing nuclear extract was snap frozen in liquid nitrogen and stored at -80°C. Protein concentration of nuclear extracts was determined by BCA assay (Pierce).

Endogenous TBP immunoprecipitation {#s4-14}
----------------------------------

Nuclear extracts from C2C12 myoblasts and myotubes were diluted with BC buffer (20 mM Tris-HCl, pH 7.2, 0.2 mM EDTA, 1.5 mM MgCl~2~, 10 mM β-mercaptoethanol, 20% glycerol, 0.5 mM PMSF and protease and phosphatase inhibitor cocktail \[Roche\]) to a final KCl concentration of 150 mM. Protein concentration was measured using a BCA assay (Pierce). Before immunopreipitation, 250 µl (200 µg proteins) of nuclear extracts were precleared with 50 µl protein G-coated magnetic beads (Life Technologies by Thermo Fisher Scientific, Waltham, MA, USA) for 1 hr at 4°C. After pre-clearing, nuclear extracts were incubated overnight at 4°C with 10 µg of anti-TBP antibody (3TF1-3G3, mouse monoclonal) ([@bib4]) or with 10 µg of non-specific mouse IgG (sc-2025, Santa Cruz, Dallas, TX, USA) cross-linked to protein G-coated magnetic beads using dimethyl pimelimidate, in the presence of 125 Units Benzonase (Novagen by Merck Millipore, Billerica, MA, USA). Protein G-bound immunocomplexes were washed seven times with BC buffer containing 150 mM KCl, and once with BC buffer containing 300 mM KCl. Isolated immunocomplexes were eluted from beads by incubation of samples with 60 µl of 1 mg/ml TBP peptide (PA81, synthetized by GenScript, Piscataway Township, NJ, USA) in BC buffer containing 150 mM KCl for 3 hr on ice.

Glycerol gradient size fractionation of protein complexes {#s4-15}
---------------------------------------------------------

3.6 ml of 10--55% glycerol gradient was prepared by sequential layering of ten aliquots of 360 µl of BC buffer (150 mM KCl, 20 mM Tris-HCl, pH 7.2, 0.2 mM EDTA, 1.5 mM MgCl2, 10 mM β-mercaptoethanol, 20% glycerol, 0.5 mM PMSF ) containing and 55, 50, 45, 40, 35, 30, 25, 20, 15 and 10% glycerol. Nuclear extract was dialyzed against BC buffer containing 150 mM KCl and 8% glycerol at 4°C for 3 hr and spun down at 14,000 g for 15 min. 500 µg of dialyzed C2C12 nuclear extract was loaded onto 3.6 ml of 10--55% glycerol gradient, and size fractionated by centrifugation at 45,000 rpm for 16 hr in SW55Ti rotor (Beckman Coulter, Carlsbad, CA, USA) at 4°C. 19 glycerol gradient fractions of volume 200 µl were collected and analyzed by immunoblot analysis. Gel filtration molecular weight standard (Biorad, Irvine, CA, USA) containing Thyroglobulin (670 kDa), Gamma-globulin (158 kDa), Ovalbumin (44 kDa), Myoglobin (17 kDa) and Vitamin B12 (1.35 kDa) was analyzed in parallel to assess the Mw of glycerol gradient fractions. Fractions containing Mw standard were analyzed by 4--12% Tris-Glycine-SDS PAGE (Life Technologies by Thermo Fisher Scientific, Waltham, MA, USA) followed by Coomassie staining of the gels (Bio-Safe Coomassie G-250 stain, Biorad).

SDS-PAGE and immunoblot analysis {#s4-16}
--------------------------------

Proteins of either nuclear extract or total cell lysate were size separated on 4--12% gradient Tris-Glycine-SDS denaturing PAGE (Life Technologies) and transferred onto a 0.45 µm nitrocellulose blotting membrane (Protran Amersham, by GE Healthcare, Little Chalfont, United Kingdom). The membrane was blocked with 5% milk in TBST (50 mM Tris_HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20) buffer for 1 hr and subsequently probed with indicated antibodies in 5% milk in TBST buffer. Immunoblot membranes were washed with TBST and probed with goat anti-mouse or goat anti-rabbit secondary antibodies conjugated with horseradish peroxidase HRP (Biorad, Irvine, CA, USA). The signal was revealed using ECL Western Blotting Substrate (Pierce by Thermo FIsher Scientific, Waltham, MA, USA). Antibodies used for immunoblot probing were as follows: anti-TBP (3TF1-3G3, mouse monoclonal) ([@bib4]), anti-TAF1 (sc-17134, Santa Cruz), anti-TAF2 (3038, rabbit polyclonal) ([@bib44]), anti-TAF4 (32TA-2B9, mouse monoclonal) ([@bib47]), anti-TAF6 (25TA-2G7, mouse monoclonal) ([@bib47]), anti-TAF10 (6TA-2B11, mouse monoclonal) ([@bib47]), anti-TAF12 (22TA-2A1, mouse monoclonal) ([@bib47]), anti-TBP2 (2TBP-2B12, mouse monoclonal) ([@bib14]), anti-Actinin 3 (EP2531Y, Origene, Rockville, MD, USA), anti-Cyclin D1 (EP272Y, EMD Millipore), anti-Myogenin (clone F5D, Developmental Studies Hybridoma Bank), anti-Tubulin (clone DM1A, Sigma), anti-Actin (sc-8432, Santa Cruz), anti-Myosin Heavy Chain (MHC, clone MF20, Developmental Studies Hybridoma Bank).

Chromatin immuno-precipitation (ChIP) assay {#s4-17}
-------------------------------------------

C2C12 myoblasts and myotubes were collected by careful trypsinization ([@bib23]) and crosslinked in suspension in 40 ml PBS containing 1% formaldehyde for 15 min at room temperature. Formaldehyde was quenched by 0.125 mM glycine for 5 min at room temperature. Crosslinked cells were washed with cold PBS containing 1 mM PMSF. To prepare chromatin, cells were lysed in a ChIP lysis buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA pH 8.0, 0.2% SDS, 1% NP40, 0.5% Sodium Deoxycholate, 1 mM PMSF and protease and phosphatase inhibitor cocktail (Roche). Chromatin was sheared to an average DNA fragment length of 500bp using a Misonix3000 sonicator, and diluted five times with the ChIP lysis buffer lacking SDS, to the final concentration of 0.04% SDS. Samples were centrifuged and the protein concentration of soluble chromatin was determined by BCA assay (Pierce). 200 µg of chromatin was used for immunoprecipitation with 10 µl anti-TBP antibody (3TF1-3G3 mouse monoclonal) ([@bib4]) or 8 µl anti-RNAPII-S5P antibody (Active Motif, 39233, Carlsbad, CA, USA). Sample with no antibody was used as a background control. After overnight incubation of the chromatin with the antibodies at 4°C, the immunocomplexes were captured with 50 µl protein A (for RNAPII-S5P antibody) or with 50 µl protein G (for TBP antibody) magnetic beads (Life Technologies) for further 3 hr at 4°C. Magnetic bead-bound immunocomplexes were washed four times with 1 ml buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA pH 8.0, 0.1% SDS, 1% NP-40, 0.5% Sodium Deoxycholate, 1 mM PMSF, and protease and phosphatase inhibitors cocktail (Roche), followed by one wash with a 1 ml buffer containing 250 mM LiCl, 100 mM NaCl, 5 mM EDTA pH 8.0, 1% NP40, 1% Sodium Deoxycholate, and a subsequent final two washes with 1 ml TE buffer. Immunocomplexes were eluted from the beads for 15 min at 65°C with buffer containing 50 mM Tris-Cl pH 8.0, 1 mM EDTA pH 8.0 and 1% SDS. Crosslinking was reversed by incubation of the ChIP isolated immunocomplexes and the input chromatin samples at 65°C overnight in presence of 0.2 M NaCl. After 0.2 mg/ml Proteinase K treatment of samples, DNA from immunoprecipitated samples as well as DNA from 1% input was purified by phenol/chloroform extraction and ethanol precipitation. 1/50 of the purified DNA was analyzed by real-time quantitative PCR using SYBR Green PCR Master Mix (Applied Biosystems). Primers used to detect locus-specific signal are listed in [Table 1](#tbl1){ref-type="table"}. The ChIP signal is expressed as the amount of immunoprecipitated DNA relative to the input DNA (% of input).
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Decision letter

Hinnebusch

Alan G

Reviewing editor

National Institute of Child Health and Human Development

,

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"TBP/TFIID-dependent activation of MyoD target genes in skeletal muscle cells\" for consideration by *eLife*. Your article has been favourably assessed by Kevin Struhl (Senior Editor) and three peer reviewers, one of whom, Alan Hinnebusch, is a member of our Board of Reviewing Editors, and another is Marc Timmers.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As you will see from the edited reviews shown below, two of the reviewers had issues with the experiments in [Figure 1A](#fig1){ref-type="fig"} on muscle regeneration following injury and it is important that you present cross-sections early after injury to document that the starting amount of injury was similar for the WT and TBP2_KO muscles. We also ask that you analyze additional control mRNAs to achieve a set of at least 3 reference genes for the qRT-PCR analyses. We all felt that adding MS analysis of the TFIID complex in TBP immunoprecipitates would greatly strengthen the paper and increase its impact on the field; although we do not insist on it. Finally, it is important that you increase the rigor of statistical analyses of your results.

Reviewer \#1:

Previous work from the Tjian group suggested that, during skeletal muscle differentiation, canonical TFIID is replaced by a complex consisting of TBP-like factor TBP2 and TAF3, which is required for activation of muscle genes. This hypothesis has been challenged by the observation that TBP2_KO mice do not display any skeletal muscle phenotype, indicating that TBP2 is dispensable for developmental myogenesis. However, it remained possible that TBP2 was needed for the regeneration potential of skeletal muscles and the expression of muscle genes in muscle stem (satellite) cells (MuSCs). The results here are at odds with the latter possibility in revealing no defect in adult muscle regeneration or the differentiation potential of MuSCs ex vivo for TBP2 knock-out animals. The authors go on to provide evidence that TBP2 is not even expressed during differentiation of skeletal myoblasts into myotubes, although it could be detected in murine overies, while TBP and TAFs that comprise convential TFIID are readily detected. TBP2 expression can be observed in myotubes transfected with TBP2, but it has no effect on expression of muscle genes. They further demonstrate that down-regulation of TBP by siRNA impairs differentiation into large multinucleated myotubes and impaired activation of skeletal muscle specific genes. Thus, TBP2 is dispensable while TBP is required for differentiation from myoblasts to myotubes. In agreement with previous findings, they do observe a downregulation TBP and at least certain TFIID TAFs on differentiation of myoblasts to myotubes, but the residual proteins appear to assemble into TFIID, based on coIP and co-sedimentation analyses, and they are found by ChIP at the promoters of muscle genes in myotubes, but not myoblasts, at levels comparable to those seen at constitutively expressed genes and in parallel with the increased occupancies of Pol II CTD-phosphorylated on Ser5 in myotubes. These findings provide strong evidence that TBP and TAFs that comprise conventional TFIID, rather than the TBP2/TAF3 complex, mediates the induction of muscle genes by MyoD on differentiation of myoblasts to myotubes. This conclusion is in accordance with the recent report that polyglutamine repeats in TBP evokes muscle degeneration by reducing the expression of muscle-specific genes, with decreased association of TBPwith MyoD.

Major comments:

\"With abundant presence of centrally nucleated fibers in both wild- type (WT) and TBP2_KO muscles 12 days post injury -- a time point when muscle regeneration is under completion ([Figure 1A](#fig1){ref-type="fig"})\": The presence of fibers is not documented here, but needs to be.

[Figure 1](#fig1){ref-type="fig"}: What analysis was done to establish that injury actually occurred?

[Figure 2A](#fig2){ref-type="fig"}: Error bars indicating standard deviation and number of replicates (n) are required.

[Figure 3B](#fig3){ref-type="fig"}: It would be superior to quantify results from multiple replicate experiments. The statement \"Indeed, TFIID subunits were detected in C2C12 nuclear extracts prepared from both proliferating myoblasts and differentiated myotubes, with a global downregulation of most TFIID subunits also at the protein level ([Figure 4A](#fig4){ref-type="fig"})\" needs quantification of replicates to justify it, as the conclusion is not obvious for TAFs 2, 6, 10, and 12.

For all experiments in which results cannot be quantified from replicates, it is necessary to state in the legend how many times the experiment was conducted and gave similar results.

Reviewer \#2:

The manuscript by Malecova and collaborators focuses on the transcriptional regulation of MyoD target genes. The authors refer to a publication by Deato and colleagues (Deato et al., 2008), which concluded that differentiation from myoblasts to myotubes involves the replacement of the canonical TFIID by a novel complex composed of TBP2 and TAF3. This finding has been questioned by the lack of skeletal or muscular deficits in the TBP2^-/-^ mice (Gazdag et al., 2009). Malecova and collaborators extend the characterization of skeletal myogenesis in TBP2^-/-^ mice demonstrating how TBP2 ablation does not affect muscle regeneration after injury. The authors document absence of TBP2 expression in both mouse myoblast cell line C2C12 and muscle stem cells (MuSCs). In addition, they show that reduced TBP expression impairs myoblast differentiation and expression of muscle-specific genes. Using both C2C12 and primary muscle stem cells they confirmed that TBP and the TFIID complex become expressed to lower levels during myogenic differentiation. ChIP assays reveal a direct involvement of TBP in the pre-initiation complex assembly at MyoD-regulated genes.

The data presented by Malecova and colleagues contradicts the previously proposed mechanisms by Deato et al. for muscle differentiation, which were obtained in the C2C12 cell model in a clear and convincing sequence of experiments. In addition, the present study extends to primary cells and to the TBP2 deletion mice. The manuscript is well written and the results of this study are discussed in a fair and balanced manner in light of the published literature on this subject. I believe that this work represents an important addition and clarification of the role of basal transcription factors in muscle differentiation.

Major comments:

1\) In [Figure 1](#fig1){ref-type="fig"}, the authors show the regenerative and differentiation potential of MuSCs in the TBP2^-/-^ mice. To better show the results in [Figure 1A](#fig1){ref-type="fig"}, the authors should include a cross-section of notexin-injured muscles at an early time point (e.g. day 3). With this comparison, the authors can demostrate the difference between complete fiber breakdown observed at day 3 and the regeneration occurred at day 12.

2\) The full sets of qRT-PCR have been quantified using GAPDH only as reference gene. The usage of more than one single reference is not sufficient. Many metabolic genes are altered upon myogenic differentiation. Therefore, additional reference genes should be used to come to a set of at least 3 reference genes, for example by inclusding HPRT1, HMBS, SDHA, PPIA, YWHAZ and/or B2M.

3\) The authors detect the presence of the TFIID complex in myoblasts and myotubes with immunoblotting for TBP and a limited set of TBP-associated factors. Subsequently, they evaluate the integrity of the TFIID complex using a glycerol size fractionation. It would be better to investigate the TFIID complex by sensitive mass spectrometry of TBP immunoprecipitates to determine the precise composition of TFIID in myotubes.

Reviewer \#3:

In this manuscript the authors present experiments designed to test whether TBP or TBP2 is required for muscle cell gene expression. The motivation for the experiments rests on previous conflicting studies. First, Deato et al. (2007, 2008) suggested that TBP2 is required for muscle cell gene expression, replacing TBP/TFIID with an alternative complex. However, Gazdag (2009) constructed a TBP2 homozygous null mouse and showed that it was viable, that TBP2 expression was only detectable in ovaries, that skeletal muscle in the TBP2^-/-^ mice was indistinguishable from that of control animals, and that the expression of myogenic factors was unaffected in the TBP2^-/-^ null mouse.

In the current work, the authors examine the issue in greater detail, testing whether TBP2 might be required in muscle stem cells, an aspect of muscle cell function untested by Gazdag (2009). Their work presents convincing data that TBP2 is not required for expression of muscle genes in these cells, that TBP2 is not detectable in these cells, and that TBP/TFIID is present and necessary for muscle gene expression. Thus, their work agrees with and extends the previous analysis of Gazdag (2009). The experiments are solid and the conclusions are reasonable.

10.7554/eLife.12534.022

Author response

*As you will see from the edited reviews shown below, two of the reviewers had issues with the experiments in [Figure 1A](#fig1){ref-type="fig"} on muscle regeneration following injury and it is important that you present cross-sections early after injury to document that the starting amount of injury was similar for the WT and TBP2_KO muscles.*

The reviewers pointed to an issue that deserves an important premise. Healthy, unperturbed skeletal muscles are composed of myofibers whose nuclei are typically located at the periphery. Intramuscular injection of myotoxins, such as notexin, is widely used to induce regeneration (1, 2, 3, 4) and is typically ensued by an early phase of muscle degeneration characterized by myofibers necrosis, followed by inflammatory infiltration and activation of satellite cells. These events occur during the first 3-4 days post injury 3 and prevent an accurate measurement of the cross-sectional area (CSA) of myofibers, as the injured muscle area contains high amount of cellular infiltrate, with the large majority of myofibers being destroyed and/or deformed (see [Author response image 1A](#fig6){ref-type="fig"}, 3 days post injury). As such, CSA cannot be evaluated during the initial stage of regeneration. Starting from day 5 or 6 after injury, activated satellite cells begin to fuse into new myfibers and/or fuse with the pre-existing damaged myofibers (3). This regeneration process is typically completed around day 10 post myotoxin injection ([Author response image 1A](#fig6){ref-type="fig"}), resulting in the restoration of the original muscle architecture. Well-established hallmarks of regenerating muscle at this stage are: i) the presence of newly regenerating myofibers with a smaller CSA and ii) central nucleation3 ([Author response image 1A](#fig6){ref-type="fig"}, 10 days post injury). Thus, in our experiments we have considered these two hallmarks to show that WT and TBP2_KO muscles were undergoing comparable regeneration, reflecting similar extent of injury. Indeed, we reasoned that failure to regenerate or weaker regeneration process would invariably lead to absence or reduction in number of centrally nucleated fibers by day 12 post-injury. On the other hand, failure to complete the regeneration process can be detected by the persistence of the inflammatory infiltrate at day 12 post-injury.10.7554/eLife.12534.011Author response image 1.Injury decreases the CSA in regenerating myofibers to the same extend in WT and TBP2KO.(**A**) Muscle histology: Hematoxilin & Eosin staining of WT muscle crosssections at different time point of regeneration. (**B**) Immunohistochemistry: cross-sections of WT and TBP2_KO muscles were stained with anti-collagen1 and anti-collagen-3 antibodies (red) to visualize clearly the myofibers. The nuclei were counterstained with DAPI. (**C**) Mean of all cross-section areas (CSA) quantified by ImageJ for each muscle was compared between injured and unperturbed muscle, the ratio is plotted. **D**) The centrally nucleated myofibers in 1B were quantified.**DOI:** [http://dx.doi.org/10.7554/eLife.12534.011](10.7554/eLife.12534.011)

With this being taken into consideration, the inspection of injured muscles in our experimental system, revealed a comparable number of centrally nucleated fibers (see the quantification in [Author response image 1D](#fig6){ref-type="fig"}), and similar trends in changes of the CSA from unperturbed to day 12 post-injury muscles in WT and TBP2_KO mice ([Author response image 1B and C](#fig6){ref-type="fig"}). In both cases, the myofibers in injured muscles were 28% smaller compared to unperturbed muscles ([Author response image 1C](#fig6){ref-type="fig"}). Moreover, in both WT and TBP2_KO muscles the tissue architecture was restored 12 days post injury ([Figure 1A](#fig1){ref-type="fig"}; [Author response image 1B](#fig6){ref-type="fig"}). This data support our conclusion that upon an initial injury, the regeneration ability of TBP2-deficient muscles is comparable to that of WT muscles.

While we provide these additional figures to the reviewers (and readers that will have access to these comments), we do not believe that they would add any further insight to the manuscript, and therefore we did not include them in the revised version of our work. However, we are happy to include them if the reviewers/editors deem it necessary.

*We also ask that you analyze additional control mRNAs to achieve a set of at least 3 reference genes for the qRT-PCR analyses.*

We indeed appreciate this comment from the reviewers. In an attempt to make our RNA analysis more rigorous, we have set out to normalize the RT-PCR data to the geometric average of 3 reference genes (5). We have designed primers for genes suggested by reviewer \#2: *Sdha, Hprt, Ywhaz, Ppia, Hmbs,* as well as two additional ribosomal genes *Rpl10* and *Rpl0*. Primers for genes Sdha and Hmbs failed our quality control, therefore we excluded them from the analysis. Importantly, as common practice, we have reverse transcribed equal amounts of RNA into cDNA for myoblasts and myotubes. When comparing the expression of six housekeeping genes (*Gapdh, Hprt, Ywhaz, Ppia, Rpl10* and *Rpl0*), we have unfortunately noticed that majority of them are down-regulated in myotubes compared to myoblasts. We have plotted the raw Ct values for each analyzed sample to illustrate the differential expression of the analyzed potential reference genes during muscle differentiation ([Author response image 2](#fig7){ref-type="fig"}, high Ct value = low expression). The most stable gene that is in our hands not differentially expressed during muscle differentiation, considering an equal total RNA amount, is *Gapdh*. For that reason we could not take into account any of the additional tested housekeeping genes for the data normalization purpose, and thus we could not use the normalization methods including geometric average of several reference genes (5), as we initially intended. Nonetheless this comparison with a panel of analyzed housekeeping genes that are down-regulated during muscle cells differentiation reinforced our initial conclusion that *Gapdh* is the most reliable reference gene for normalization of RNA expression.10.7554/eLife.12534.012Author response image 2.Comparison of expression levels of six houskeeping genes during myoblasts to myotubes differentiation.RNA was isolated from biological triplicates of C2C12 myoblasts and myotubes as described in themanuscript (see [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Identical amount of RNA was converted to cDNA for each sample. RNA expression for six houskeeping genes was evaluated by RT-PCR: *Gapdh*,*Hprt*, *Ywhaz, Ppia, Rpl10* and *Rpl0*. Ct values for each analyzed genes were plotted, the bar represents mean of three independent samples.**DOI:** [http://dx.doi.org/10.7554/eLife.12534.012](10.7554/eLife.12534.012)

We all felt that adding MS analysis of the TFIID complex in TBP immunoprecipitates would greatly strengthen the paper and increase its impact on the field; although we do not insist on it.

Indeed, we are currently addressing this issue, within a more complex context (that is the relationship between PIC formation, SWI/SNF chromatin remodeling complex activity and H3K4 trimethylation), to possibly detect components of the basal transcription machinery that link SWI/SNF activity and activation of MyoD-regulated muscle promoters. While we acknowledge that the relationship between composition of the TFIID complex and SWI/SNF complex in myoblasts and myotubes builds directly on the discovery presented in this manuscript, we also note that it is part of an independent project that will need a substantial amount of work and that is clearly behind the timeframe of publication of the current manuscript. We will be more than glad to follow-up on this story, once ready, with a submission to *eLife*.

Finally, it is important that you increase the rigor of statistical analyses of your results.

[Figure 1B--E](#fig1){ref-type="fig"}: We have clarified the number of replicates in the figure legend.

[Figure 2A](#fig2){ref-type="fig"}: We have performed the RT-PCR experiment in triplicates, analyzing three independent skeletal muscle myotubes and ovary isolations and included the standard deviation error bars in the figure.

[Figure 3B](#fig3){ref-type="fig"}: We have repeated the siTBP experiment in triplicates. We have immunolabeled the cells with anti-MHC (Myosin Heavy Chain) MF20 antibody to better visualize and quantify the extent of C2C12 myoblasts differentiation into myotubes, and the impairment of this process when TBP is downregulated (in the absence of TBP).

[Figure 4A](#fig4){ref-type="fig"}: We have quantified the immunoblots of two independent nuclear extract preparations ([Author response image 3](#fig8){ref-type="fig"}). We agree that it is easier to appreciate the downregulation of most of the TFIID subunits (except TAF2) on the protein level with the immunoblot quantification analysis. However, we have also noted that the antibodies against TBP, TAF2, TAF6, TAF10, MHC and Cyclin D1 do not react accordingly to the two-fold difference in amount of nuclear extract proteins on the immunoblot, since the quantified signals showed more than two-fold decrease in samples that were half amount of proteins. Therefore we believe that it would be incorrect and misleading to make any further quantitative conclusions about the extent of downregulation of the TFIID subunits on the protein level based on the immunoblot quantification. Therefore we are providing the quantification of immunoblot of two independent C2C12 myoblasts and myotubes preparation for an illustrative purpose in [Author response image 3](#fig8){ref-type="fig"}.10.7554/eLife.12534.013Author response image 3.Downregulation of TFIID subunits on protein level - two independent nuclear extract (NE) preparations.(**A**) Original figure in the manuscript ([Figure 4A](#fig4){ref-type="fig"}). (****B****) Immunoblot analysis of independent nuclear extract preparation. In panel B signals for TBP and TAF12 were not possible to quantify due to a high background:signal ratio. Immunoblot signal was quantified with ImageJ.**DOI:** [http://dx.doi.org/10.7554/eLife.12534.013](10.7554/eLife.12534.013)

[Figure 5](#fig5){ref-type="fig"}: We have performed the ChIP experiment in C2C12 myoblasts and myotubes twice. In both independent experiments we have seen a similar extent of recruitment of TBP and RNAPII-S5P specifically at the promoters of muscle genes only in differentiated myotubes. Moreover, we have also performed ChIP experiments in our lab in differentiated C2C12 cells under the conditions of impaired skeletal muscle differentiation, when we downregulated Brg1 subunit of SWI/SNF chomatin remodeling complex (6, 7, 8). We observed that interference with the differentiation process leads to the targeted loss of recruitment of TBP and RNAPII-S5P on muscle promoters in our ChIP assays (data not shown).

We have performed Student's t test statistical analysis on the data in [Figure 1C, 1E](#fig1){ref-type="fig"}, [Figure 2C](#fig2){ref-type="fig"}, [Figure 3B, 3D](#fig3){ref-type="fig"} and in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. The resulting p-values are indicated in the respective figures.

[Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}: Since the main purpose of the RNA-seq data presentation in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} is to demonstrate the absence of TBP2 expression in skeletal myoblasts and myotubes, we think it is sufficient to present the figure in the paper as RNA-seq enrichment on the genome browser. Moreover, this visualization shows the quality of the RNA-seq data. Additionally, we have included the plots of normalized reads for genes relevant to this work in IMR90 conversion to skeletal muscle from an RNA-seq performed in our lab in collaboration with Dr. Ren\'s lab ([Author response image 4](#fig9){ref-type="fig"}). The RNA-seq analysis of myoblasts and myotubes supports the RT-PCR analysis outcome presented on [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} in regard to TBP downregulation during myoblasts to myotubes differentiation. According to the suggestion of Reviewer \#1 regarding the [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, we have modified the figure to better represent the differences in gene structure between murine (C2C12) and human (IMR90) cells to avoid confusion.10.7554/eLife.12534.014Author response image 4.Graphical representation of normalized RNA-seq data in human IMR90 fibroblasts overexpressing MyoD grown in growth media GM (myoblasts) or differentiated in differentiation media DM (myotubes).**DOI:** [http://dx.doi.org/10.7554/eLife.12534.014](10.7554/eLife.12534.014)
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